DrugPatentWatch Database Preview
INTELENCE Drug Profile
Which patents cover Intelence, and what generic alternatives are available?
Intelence is a drug marketed by Janssen R And D and is included in one NDA. There are four patents protecting this drug.
The generic ingredient in INTELENCE is etravirine. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the etravirine profile page.
Summary for INTELENCE
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 81 |
| Clinical Trials: | 12 |
| Patent Applications: | 1,288 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for INTELENCE |
| DailyMed Link: | INTELENCE at DailyMed |
Generic Entry Opportunity Date for INTELENCE
Generic Entry Date for INTELENCE*:
Constraining patent/regulatory exclusivity:
PEDIATRIC EXCLUSIVITY NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for INTELENCE
| Ingredient-type | Non-Nucleoside Analog |
| Drug Class | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor |
| Mechanism of Action | Non-Nucleoside Reverse Transcriptase Inhibitors |
Synonyms for INTELENCE
| 0C50HW4FO1 |
| 1142096-06-7 |
| 269055-15-4 |
| 394729-17-0 |
| 3m8p |
| 4-((6-amino-5-bromo-2-((4-cyanophenyl) amino) pyrimidin-4-yl) oxy)-3, 5-dimethylbenzonitrile |
| 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl-benzonitrile |
| 4-((6-Amino-5-bromo-2-((4-cyanophenyl)amino)pyrimidin-4-yl)oxy)-3,5-dimethylbenzonitrile |
| 4-({6-AMINO-5-BROMO-2-[(4-CYANOPHENYL)AMINO]PYRIMIDIN-4-YL}OXY)-3,5-DIMETHYLBENZONITRILE |
| 4-(6-amino-5-bromo-2-(4-cyanophenylamino)pyrimidin-4-ylamino)-3,5-dimethylbenzonitrile |
| 4-(6-amino-5-bromo-2-(4-cyanophenylamino)pyrimidin-4-yloxy)-3,5-dimethylbenzonitrile |
| 4-[[4-amino 5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile |
| 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]-amino]benzonitrile |
| 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]-benzonitrile |
| 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]-benzonitrile; |
| 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile |
| 4-[[6-amino-5-bromo-2-(4-cyanoanilino)-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile |
| 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3, 5 Cdimethylbenzonitrile |
| 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl benzonitrile |
| 4-[[6-AMINO-5-BROMO-2-[(4-CYANOPHENYL)AMINO]-4-PYRIMIDINYL]OXY]-3,5-DIMETHYLBENZONITRILE |
| 4-[6-amino-5-bromo-2-(4-cyano-phenylamino)-pyrimidin-4-yloxy]-3,5-dimethyl-benzonitrile |
| 4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethyl-benzonitrile |
| 4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile |
| 4-[6-amino-5-bromo-2-[ amino]pyrimidin-4-yl]oxy-3,5-dimethyl-benzonitrile |
| 4-[6-AMINO-5-BROMO-2-[(4-CYANOPHENYL)AMINO]PYRIMIDIN-4-YL]OXY-3,5-DIMETHYL-BENZONITRILE |
| 4-[6-azanyl-5-bromanyl-2-[(4-cyanophenyl)amino]pyrimidin-4-yl]oxy-3,5-dimethyl-benzenecarbonitrile |
| 4CA-0516 |
| 65B |
| A818671 |
| AB0030712 |
| AB01566873_01 |
| ABP001081 |
| AC-8503 |
| AC1L4XC5 |
| ACM1142096067 |
| ACM1189671484 |
| AK172046 |
| AKOS015896355 |
| AM20080899 |
| AN-6704 |
| API0007220 |
| B-1795 |
| BC004800 |
| BC228657 |
| BCP0726000193 |
| BCP9000006 |
| BDBM50103642 |
| Benzonitrile, 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl- |
| Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- |
| C20H15BrN6O |
| cc-89 |
| CHEBI:63589 |
| CHEMBL308954 |
| CM14420 |
| CS-0435 |
| CTK4I1392 |
| D04112 |
| D0BP9C |
| DAPY deriv |
| DB-067700 |
| DB06414 |
| Diaminopyrimidine deriv |
| DTXSID30181412 |
| EBD13985 |
| etravirin |
| Etravirine |
| Etravirine (JAN/USAN/INN) |
| Etravirine (TMC125) |
| Etravirine-d8 |
| etravirine; |
| FT-0658058 |
| HE-0088 |
| HE068441 |
| HE330415 |
| HMS3651P20 |
| HY-90005 |
| I06-1887 |
| Intelence (TN) |
| Intelence(TM) |
| J-513179 |
| KB-51834 |
| MFCD09837879 |
| MolPort-009-194-145 |
| PB32778 |
| PL052624 |
| PubChem22565 |
| PYGWGZALEOIKDF-UHFFFAOYSA-N |
| R 165335 |
| R-165335 |
| R165335 |
| R165335-TMC125 |
| R165335; |
| R165355; |
| RP17742 |
| RTX-010809 |
| s3080 |
| SC-44935 |
| SCHEMBL52691 |
| SR-01000944895 |
| SR-01000944895-1 |
| ST1251359 |
| ST51053273 |
| TMC 125 |
| TMC 125; |
| TMC-125 |
| TMC-125; |
| TMC-125/R-165335 |
| TMC125 |
| UNII-0C50HW4FO1 |
| X2931 |
| ZINC602632 |
US Patents and Regulatory Information for INTELENCE
International Patents for INTELENCE
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Spain | 2193664 | ➤ Try a Free Trial |
| African Intellectual Property Organization (OAPI) | 12029 | ➤ Try a Free Trial |
| Hungary | 228449 | ➤ Try a Free Trial |
| Israel | 148801 | ➤ Try a Free Trial |
| European Patent Office | 1129079 | ➤ Try a Free Trial |
| Czech Republic | 20020907 | ➤ Try a Free Trial |
| Mexico | PA02003182 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for INTELENCE
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2009000003 | Germany | ➤ Try a Free Trial | PRODUCT NAME: ETRAVIRIN UND DESSEN ADDITIONSSALZE; REGISTRATION NO/DATE: EU/1/08/468/001 20080828 |
| 2008016,C1002795 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: ETRAVIRINUM; REGISTRATION NO/DATE: EU/1/08/468/001 20080828 |
| 7 | Finland | ➤ Try a Free Trial | |
| 2009 00004 | Denmark | ➤ Try a Free Trial | |
| C/GB09/003 | United Kingdom | ➤ Try a Free Trial | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB09/003 GRANTED TO JANSSEN PHARMACEUTICA NV IN RESPECT OF THE PRODUCT ETRAVIRINE OPTIONALLY IN A FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6342 DATED 08 DECEMBER 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 AUGUST 2023. |
| C033/2008 | Ireland | ➤ Try a Free Trial | SPC033/2008: 20090914, EXPIRES: 20230827 |
| 0373 | Netherlands | ➤ Try a Free Trial | 300373, 20191101, EXPIRES: 20230827 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
